Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

• Status: RECRUITING
• Trial end date: 2030-04-01

Summary

The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.

• Phase: PHASE3

Details

• Lead Sponsor: Jazz Pharmaceuticals
• Treatments: Cisplatin; durvalumab; Gemcitabine; pembrolizumab; zanidatamab